Recovery Profiles of Sevoflurane and Desflurane with or without M-Entropy Guidance in Obese Patients: A Randomized Controlled Trial

Yu-Ming Wu 1,2, Yen-Hao Su 3,4, Shih-Yu Huang 1,2, Po-Han Lo 1,2, Jui-Tai Chen 1,2, Hung-Chi Chang 1,2, Yun-Ling Yang 1, Yih-Giun Cherng 1,2 *, Hsiang-Ling Wu 5,6 and Ying-Hsuan Tai 1,2, *#*©

1 Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan; 15538@tsmu.edu.tw (Y.-M.W.); 10689@tsmu.edu.tw (S.-Y.H.); 12006@tsmu.edu.tw (P.-H.L.); 19240@tsmu.edu.tw (J.-T.C.); 09331@tsmu.edu.tw (H.-C.C.); 10500@tsmu.edu.tw (Y.-L.Y.); stainless@tsmu.edu.tw (Y.-G.C.)
2 Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
3 Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan; su11066@tsmu.edu.tw
4 Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
5 Department of Anesthesiology, Taipei Veterans General Hospital, Taipei 11217, Taiwan; hlwu9@vghtpe.gov.tw
6 School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan
* Correspondence: 18045@s.tmu.edu.tw; Tel.: +886-2-27361661 (ext. 3229); Fax: +886-2-27390500

Abstract: Obesity increases the risk of prolonged emergence from general anesthesia due to the delayed release of anesthetic agents from body fat. This trial aimed to evaluate the effects of sevoflurane and desflurane along with anesthetic depth monitoring on emergence time from anesthesia in obese patients. Adults with a body mass index ≥ 30 kg·m⁻² undergoing laparoscopic sleeve gastrectomy at a medical center were randomized into four groups: sevoflurane or desflurane anesthesia with or without M-Entropy guidance on anesthetic depth monitoring. In the M-Entropy guidance groups, the dosage of sevoflurane and desflurane was adjusted to achieve response and state entropy values between 40 and 60 during surgery. In the non-M-Entropy guidance groups, the dosage of anesthetics was titrated according to clinical signs. Primary outcome was time to spontaneous eye opening. A total of 80 participants were randomized. Compared to sevoflurane, desflurane anesthesia significantly reduced the time to spontaneous eye opening [mean difference (MD): −129 s; 95% confidence interval (CI): −211, −46], obeying commands (−160; −243, −77), tracheal extubation (−172; −266, −78), and leaving operating room (−148; −243, −54). M-Entropy guidance further reduced time to eye opening (MD: −142 s; 99.2% CI: −276, −8), tracheal extubation (−199; −379, −19), and leaving operating room (−190; −358, −23) in the desflurane but not the sevoflurane group. M-Entropy guidance significantly reduced the risk of agitation during emergence, i.e., risk difference: −0.275 (95% CI: −0.464, −0.086); and number needed to treat: 4. Compared to sevoflurane, using desflurane to maintain general anesthesia accelerated the return of consciousness in obese patients. M-Entropy guidance further hastened awakening in patients using desflurane and prevented emergence agitation.

Keywords: bariatric surgery; depth of anesthesia; electroencephalographic monitoring; emergence agitation; morbid obesity

1. Introduction

Obesity is a growing epidemic, affecting about 650 million adults worldwide in 2016 [1]. The global prevalence of obesity has almost tripled in the past four decades, exerting a heavy burden on healthcare system [1,2]. Obesity substantially increases the
risks of metabolic, cardiovascular, and respiratory diseases, as well as several types of cancer [3]. The global volume of surgery for obese patients is forecast to increase as a result of the growing prevalence of, and diseases related to, obesity [4].

Recovery from general anesthesia may be compromised in obese patients due to the delayed release of lipid-soluble anesthetic agents from excessive adipose tissue [5]. In addition, obese patients are susceptible to the respiratory depression effects of anesthetics, which potentiates the development of respiratory adverse events (e.g., airway obstruction and hypoxemia) after surgery [6]. The latest Enhanced Recovery After Surgery (ERAS) guidelines do not recommend specific anesthetic regimens for early emergence from general anesthesia in bariatric surgery due to conflicting results in the current literature [7–16]. Some studies reported that desflurane has a consistent and rapid recovery profile in the obese population compared to sevoflurane, isoflurane and propofol [8–13]. However, other investigators demonstrated similar awakening times between sevoflurane and desflurane anesthesia [14–16]. Overall, the current evidence is insufficient to determine the optimal anesthetic agent for obese patients in terms of immediate recovery from general anesthesia.

Electroencephalography (EEG) neuromonitoring is effective in guiding an optimal range of anesthetic depth during general anesthesia [17]. A meta-analysis showed that bispectral index (BIS)-guided anesthesia enhances emergence from general anesthesia in nonobese patients compared to clinical signs [17]. However, the effect of anesthetic depth monitoring on emergence from anesthesia remains largely unexplored in obese patients [18,19]. Furthermore, there are few studies examining the interplay between different anesthetic agents and EEG neuromonitoring and their joint effect on anesthetic emergence in obese patients.

We conducted a prospective, four-arm, randomized controlled trial to investigate the effects of desflurane versus sevoflurane, together with spectral entropy monitoring, for anesthetic depth on emergence time from general anesthesia in obese patients. Specifically, we hypothesized that using desflurane for maintenance of anesthesia along with spectral entropy monitoring reduce the time to emergence from anesthesia in obese patients undergoing bariatric surgery.

2. Materials and Methods

This trial obtained the approval from the Joint Institutional Review Board of Taipei Medical University in Taiwan (TMU-JIRB-N202002076). It was registered in an international directory, www.clinicaltrials.gov (accessed on 27 September 2021) (identifier: NCT04395248). Informed verbal and written consent were obtained from all participants before randomization. This study was performed in accordance with the Helsinki Declaration and relevant regulations.

2.1. Patient Selection Criteria

We conducted a four-arm parallel randomized controlled trial to prospectively recruit patients undergoing laparoscopic sleeve gastrectomy at a medical center between May 2020 and August 2021. Inclusion criteria were age 20 to 65 years and body mass index equal to or greater than 30 kg m$^{-2}$. Exclusion criteria were use of hypnotics or antipsychotics within 30 days before surgery, known cerebrovascular disease, stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate < 30 mL min$^{-1}$ 1.73 m$^{-2}$), significant cardiovascular disease (e.g., coronary artery disease and previous aortic dissection), peripheral capillary oxygen saturation < 90% in room air, pregnant women, and patient refusal (Figure 1). All operations were performed by the same team of surgeons, using the same surgical techniques.
Figure 1. Consolidated Standards of Reporting Trials flow diagram. † Not mutually exclusive, since patients could have more than one exclusion criterion.

2.2. Randomization Methods

Patients were randomly allocated into four groups (sevoflurane without M-Entropy guidance, sevoflurane with M-Entropy guidance, desflurane without M-Entropy guidance, and desflurane with M-Entropy guidance) in a ratio of 1:1:1:1. The RAND function of Statistics Analysis System (SAS), version 9.4 (SAS Institute Inc., Cary, NC, USA) was used to produce a sequence of random permuted blocks of four. After obtaining informed consent, each patient was given a unique identifier and a group assignment by the principal investigator. The assignments were then enclosed in envelopes and sealed. An independent attending anesthesiologist (Y.-M.W. or S.-Y.H.) opened the relevant envelope upon the patient’s arrival at the operating room and administered the assigned intervention.

2.3. Anesthesia Management and M-Entropy Guidance

In the operating room, a M-Entropy™ sensor and a S/5™ module (GE Healthcare, Helsinki, Finland) were applied to all patients’ foreheads before induction of anesthesia, according to the manufacturer’s recommendations. This was connected to a M-Entropy monitor that was concealed from the patient and surgeons. General anesthesia was induced with propofol at a dose of 1.5–2.0 mg·kg$^{-1}$ body weight and fentanyl 2–3 µg·kg$^{-1}$ total body weight. An infusion of rocuronium 0.8–1.0 mg·kg$^{-1}$ body weight was administered to facilitate endotracheal intubation. After intubation, pressure-controlled ventilation with a peak pressure < 30 cm H$_2$O and a positive end expiratory pressure of 5 cm H$_2$O was applied to achieve a tidal volume 8–10 mL·kg$^{-1}$ ideal body weight and a respiratory...
rate of 10–15 min⁻¹, as well as to maintain end-tidal carbon dioxide below 45 mm Hg during surgery. The inspiratory oxygen fraction was set between 0.6 and 0.8 to maintain peripheral capillary oxygen saturation above 95%. Anesthesia was maintained using volatile anesthetics of sevoflurane or desflurane with a fresh gas flow of 6 L·min⁻¹ during the first 5 min, and 1.5–2 L·min⁻¹ thereafter. The vaporizer was set at 2 vol% for sevoflurane and 6 vol% for desflurane during the first 5 min.

In the M-Entropy guidance groups, the dosage of sevoflurane and desflurane was adjusted to achieve response and state entropy values between 40 and 60. In the non-M-Entropy guidance groups, the dosage of anesthetics was titrated according to clinical signs and judgement. Typically, this was to maintain a mean arterial pressure within a 20% range of the baseline and a heart rate within the range 50 to 100 beats·min⁻¹. In case of signs of inadequate anesthesia (e.g., movement, cough, and swallowing), the anesthetic dosage was increased. M-Entropy monitoring was continued in the non-M-Entropy groups, but the entropy values were concealed from the anesthetist in charge. Entropy values, hemodynamic, and expiratory gas data were recorded in 5-min intervals. At the end of wound closure, volatile anesthetics were discontinued, and the fresh gas flow was returned to 6 L·min⁻¹ with 100% oxygen. Once the train-of-four count recovered to 1–4, sugammadex dosed at 2 mg·kg⁻¹ ideal body weight +40% was administered to reverse neuromuscular blockade [20]. Manual-breathing support was then used to maintain end-tidal carbon dioxide below 45 mm Hg until the return of spontaneous ventilation.

2.4. Outcome Measurement

Primary outcome was time to spontaneous eye opening, defined as the interval between cessation of volatile anesthetics and patient’s eye opening. Secondary outcomes included time to obeying verbal command (sustained head lift or handgrip for 5 s), tracheal extubation, and leaving operating room, as well as events of agitation or drowsiness during emergence. The Richmond Agitation-Sedation Scale (RASS) was used to evaluate the levels of agitation and sedation [21]. Agitation was defined as a RASS score +2 to +4, and drowsiness as −2 to −5. Patients and surgeons were blinded to group allocations. In addition, the anesthetic and M-Entropy monitors were concealed from an independent nurse anesthetist (Y.-L.Y.), who was blinded to group allocations. This anesthetist determined the time to recovery from anesthesia and measured the levels of agitation and sedation during emergence.

2.5. Sample Size Estimation

According to a prior study, at least 36 patients in each group of sevoflurane or desflurane are needed to detect a difference of 186 s of time to spontaneous eye opening, accepting a type I error of 5% and type II error of 20%, with a mean anticipated time to eye opening of 450 s and a standard deviation of 200 s in the sevoflurane group [22,23]. We enrolled 40 subjects in each group to compensate for possible dropouts.

2.6. Statistical Analysis

Shapiro-Wilk tests and Kolmogorov-Smirnov tests were used to examine the normality of included variables. Normally distributed variables were summarized using mean ± standard deviation. Non-normally distributed data were presented as medians with interquartile range, minimum, and maximum. The distributions of baseline patient characteristics and outcome variables were compared across four groups using ANOVA or Kruskal-Wallis tests for continuous variables, as appropriate. Chi-square tests or Fisher’s exact tests were used to compare categorical variables across four groups, as appropriate. For pairwise comparisons, either t tests or Mann-Whitney U tests were used for continuous variables, and chi-square tests or Fisher’s exact tests for categorical variables. We considered p < 0.05 to be statistically significant for a two-sided test. A Bonferroni correction to the significance criterion was applied for multiple pairwise comparisons. All the statistical analyses were conducted using SAS software.
3. Results

3.1. Baseline Patient and Clinical Characteristics

Table 1 shows the baseline characteristics of the enrolled patients. The distributions of demographics, body mass index, American Society of Anesthesiologists physical status, lifestyle factors, and coexisting diseases were generally balanced across the four groups. Regarding preoperative laboratory data, there was a significant difference in the estimated glomerular filtration rate across the four groups, but pairwise comparisons did not show any differences among groups (data not shown). There was no difference in the baseline response and state entropy values, doses of intravenous anesthetics, duration of anesthesia, or amount of intravenous fluids among the four groups, either (Table 2).

Table 1. Baseline patient characteristics.

|                     | SEVO without M-Entropy n = 20 | SEVO with M-Entropy n = 20 | DES without M-Entropy n = 20 | DES with M-Entropy n = 20 | p     |
|---------------------|-------------------------------|----------------------------|-----------------------------|--------------------------|-------|
| Age, years          | 38.0 ± 7.3                    | 37.9 ± 10.7                | 37.0 ± 10.5                 | 33.9 ± 7.5               | 0.447 |
| Sex, male           | 12 (60.0%)                    | 7 (35.0%)                  | 11 (55.0%)                  | 8 (40.0%)                | 0.3328|
| Body mass index, kg·m⁻² | 41.4 ± (37.5, 46.4)           | 38.3 ± (34.4, 41.8)        | 41.2 ± (37.2, 47.5)         | 39.3 ± (34.4, 42.2)      | 0.2512|
| Body mass index, binary, kg·m⁻² | < 40 8 (40.0%)                | 12 (60.0%)                 | 8 (40.0%)                   | 11 (55.0%)               | 0.4660|
| Waist circumference, cm | 126.0 ± 12.6                 | 125.4 ± 14.1               | 127.0 ± 17.5                | 122.6 ± 12.9             | 0.7919|
| ASA physical status |                               |                           |                             |                          |       |
| II                  | 8 (40.0%)                     | 12 (60.0%)                 | 8 (40.0%)                   | 11 (55.0%)               | 0.4660|
| III                 | 12 (60.0%)                    | 8 (40.0%)                  | 12 (60.0%)                  | 9 (45.0%)                |       |
| Current cigarette smoking | 7 (35.0%)                    | 6 (30.0%)                  | 11 (55.0%)                  | 10 (50.0%)               | 0.3236|
| Current alcohol drinking | 4 (20.0%)                     | 4 (20.0%)                  | 4 (20.0%)                   | 2 (10.0%)                | 0.8177|
| Coexisting disease  |                               |                           |                             |                          |       |
| Hypertension        | 11 (55.0%)                    | 5 (25.0%)                  | 7 (35.0%)                   | 4 (20.0%)                | 0.0925|
| Diabetes mellitus   | 3 (15.0%)                     | 3 (15.0%)                  | 4 (20.0%)                   | 4 (20.0%)                | >0.9999|
| Obstructive sleep apnea | 8 (40.0%)                    | 9 (45.0%)                  | 9 (45.0%)                   | 6 (30.0%)                | 0.7410|
| Fatty liver         | 17 (85.0%)                    | 15 (75.0%)                 | 15 (75.0%)                  | 17 (85.0%)               | 0.7949|
| Preoperative blood test |                           |                           |                             |                          |       |
| Hemoglobin, g·dL⁻¹  | 14.7 ± (12.3, 15.5)           | 14.3 ± (12.7, 17.8)        | 14.8 ± (12.5, 15.8)         | 14.5 ± (13.9, 15.1)      | 0.4802|
| eGFR, mL·min⁻¹·1.73 m⁻² | 93.5 ± (84.4, 116.5)          | 119.9 ± (103.1, 129.3)     | 99.2 ± (82.8, 153.9)        | 121.9 ± (87.0, 126.8)    | 0.0105|
| Sodium, mmol·L⁻¹    | 139 ± (136, 144)              | 139 ± (130, 145)           | 139 ± (135, 144)            | 138 ± (134, 143)         | 0.8009|
| Potassium, mmol·L⁻¹ | 3.9 ± (3.3, 4.4)              | 3.9 ± (3.4, 4.4)           | 3.8 ± (3.5, 4.4)            | 4.1 ± (3.3, 4.2)         | 0.4356|
| Alanine aminotransferase, U·L⁻¹ | 30 ± (27, 40)               | 34 ± (25, 44)              | 28 ± (15, 35)               | 36 ± (20, 23)            | 0.5160|
| Aspartate aminotransferase, U·L⁻¹ | 34 ± (21, 44)               | 37 ± (23, 58)              | 33 ± (22, 38)               | 40 ± (23, 69)            | 0.4865|

Values are mean with standard deviation, counts with percent, or median with interquartile range (minimum and maximum). Abbreviations: ASA, American Society of Anesthesiologists; DES, desflurane; eGFR, estimated glomerular filtration rate; SEVO, sevoflurane.

3.2. Intraoperative Hemodynamic Changes

The heart rate, mean arterial pressure, body temperature, and peripheral capillary oxygen saturation among the four groups were generally comparable before and after induction of anesthesia, during pneumoperitoneum, at the cessation of volatile anesthetics, and after tracheal extubation (Supplementary Table S1). There was a difference in the body temperature at 5 min after start of pneumoperitoneum across groups, but pairwise comparisons showed no difference among groups (data not shown).
Table 2. Baseline entropy values and intraoperative anesthetic parameters.

|                              | SEVO without M-Entropy | SEVO with M-Entropy | DES without M-Entropy | DES with M-Entropy | p   |
|------------------------------|------------------------|---------------------|-----------------------|--------------------|-----|
| **RE value before induction**|                        |                     |                       |                    |     |
| n = 20                       | 98                     | 97, 99 (93, 100)    | 98                    | 97, 99 (95, 100)   |     |
| **SE value before induction**| 88                     | 87, 90 (86, 94)     | 88                    | 86, 89 (82, 90)    | 0.6215 |
| Intravenous anesthetics      |                        |                     |                       |                    |     |
| Lidocaine, mg                | 100                    | 80, 100 (60, 100)   | 80                    | 80, 100 (60, 100)  |     |
| Fentanyl, µg                 | 200                    | 150, 200 (150, 250) | 175                   | 150, 200 (150, 250)|    |
| Propofol, mg                 | 200                    | 155, 200 (150, 200) | 160                   | 145, 200 (130, 200)|    |
| Dexamethasone, mg            | 5                      | 5 (5, 5)            | 5                     | 5 (5, 5)           | 0.896 |
| Glycopyrrolate, mg           | 0.2                    | 0.2 (0.2, 0.2)      | 0.2                   | 0.2 (0.2, 0.2)     | 0.3515 |
| Rocuronium, mg               | 100                    | 75, 115 (75, 140)   | 95                    | 80, 100 (60, 100)  |     |
| Sugammadex, mg               | 185                    | 150, 200 (135, 220) | 165                   | 155, 193 (150, 200)|    |
| Duration of anesthesia, min  | 120                    | 110, 148 (75, 280)  | 116                   | 100, 135 (90, 210) |    |
| Amount of intravenous fluids, mL | 800                  | 625, 1000 (350, 1350)| 750                   | 550, 1000 (350, 1200)| 0.5477 |

Values are median with interquartile range (minimum and maximum). Abbreviations: DES, desflurane; RE, response entropy; SE, state entropy; SEVO, sevoflurane.

3.3. Study Outcomes

Compared to sevoflurane, desflurane anesthesia significantly reduced time to spontaneous eye opening [mean difference (MD): −129 s, 95% confidence interval (CI): −211, −46], obeying commands (MD: −160 s, 95% CI: −243, −77), tracheal extubation (MD: −172 s, 95% CI: −266, −78), and leaving operating room (MD: −148 s, 95% CI: −243, −54). In addition, desflurane was associated with lower average values of response and state entropy and higher time percentages of response, as well as state entropy values < 40 compared to sevoflurane (Table 3). There was no difference in the rate of emergence agitation between sevoflurane and desflurane.

3.4. Study Outcomes

Compared to sevoflurane, desflurane anesthesia significantly reduced time to spontaneous eye opening [mean difference (MD): −129 s, 95% confidence interval (CI): −211, −46], obeying commands (MD: −160 s, 95% CI: −243, −77), tracheal extubation (MD: −172 s, 95% CI: −266, −78), and leaving operating room (MD: −148 s, 95% CI: −243, −54). In addition, desflurane was associated with lower average values of response and state entropy and higher time percentages of response, as well as state entropy values < 40 compared to sevoflurane (Table 3). There was no difference in the rate of emergence agitation between sevoflurane and desflurane.

Overall, M-entropy guidance did not affect times to spontaneous eye opening, obeying commands, tracheal extubation, or leaving operating room (Table 3). However, M-Entropy guidance significantly decreased time to spontaneous eye opening (MD: −142 s, 99.2% CI: −276, −8), tracheal extubation (MD: −199 s, 99.2% CI: −379, −19), and leaving operating room (MD: −190 s, 99.2% CI: −358, −23) in patients receiving desflurane anesthesia (Tables 4 and 5). In addition, M-Entropy guidance reduced the risk of emergence agitation, with a risk difference of −0.275 (95% CI: −0.464, −0.086) and a number needed to treat of 4 (Table 3). M-Entropy guidance was associated with higher time percentages of response and state entropy values ranging from 40 to 60. The average response and state entropy values of M-Entropy guidance groups were significantly higher than those without M-Entropy guidance. In addition, M-Entropy guidance significantly reduced the average age-adjusted minimum alveolar concentration of end-tidal desflurane, but not sevoflurane, during surgery.
Table 3. Study outcomes of desflurane versus sevoflurane and M-Entropy guidance versus no guidance.

|                  | Sevoflurane Anesthesia | No M-Entropy Guidance | M-Entropy Guidance |
|------------------|------------------------|------------------------|---------------------|
|                  | n = 40                 | n = 40                 | n = 40              |
| Time to spontaneous eye opening, s | 454 (149, 982) | 315 (121, 278) | 0.0034 | 372 (125, 398) | 333 (121, 814) | 0.0922 |
| Time to obeying commands, s | 494 (222, 925) | 361 (130, 825) | <0.0001 | 422 (180, 1158) | 384 (130, 884) | 0.1060 |
| Time to tracheal extubation, s | 571 (232, 1060) | 385 (160, 1144) | 0.0001 | 504 (206, 1144) | 412 (211, 590) | 0.0675 |
| Time to leaving operating room, s | 849 (443, 1400) | 683 (410, 1255) | 0.0008 | 765 (443, 1372) | 707 (443, 1400) | 0.1658 |
| Emergence agitation | 13 (25.1) | 10 (25.1) | 0.4586 | 17 (42.5) | 6 (15.8) | 0.0067 |
| Drowsiness after tracheal extubation | 3 (2) | 2 (2) | >0.9999 | 2 (2) | 3 (7.5) | >0.9999 |
| Intraoperative awareness or recall | 0 | 0 | NA | 0 | 0 | NA |
| Time percentage of RE > 60 | 24.4 | 12.0 | 0.0004 | 15.5 | 8.3 | 0.5745 |
| Time percentage of SE > 60 | 61.6 | 72.2 | 0.2346 | 51.7 | 30.2 | <0.0001 |
| Time percentage of RE < 40 | 3.8 | 8.3 | 0.0589 | 17.4 | 1.4 | <0.0001 |
| Average RE value | 56 (41, 68) | 52 | 0.0002 | 50 | 4.5 | 0.0045 |
| Time percentage of SE > 60 | 21.1 | 11.0 | 0.0010 | 12.8 | 7.1 | <0.0001 |
| Time percentage of SE < 40 | 67.4 | 71.0 | 0.8663 | 50.0 | 34.1 | <0.0011 |
| Average SE value | 55 (49, 60) | 50 | 0.0003 | 48 | 4.3 | 0.0637 |
| Average level of end-tidal SEVO, % | 1.63 | 1.21 | 1.66 | 1 (1.2) | 1.54 | 0.4091 |
| Average level of end-tidal SEVO, aaMAC | 0.76 | 0.57 | 0.78 | 0.7 (0.9) | 0.66 | 0.1465 |
| Average level of end-tidal DES, % | NA | NA | 4.85 | 4.3 | 4.41 | 0.0531 |
| Average level of end-tidal DES, aaMAC | NA | NA | 0.67 | 0.6 | 0.64 | 0.0358 |

Values are counts with percent or median with interquartile range (minimum and maximum). Abbreviation: aaMAC, age-adjusted minimum alveolar concentration; DES, desflurane; RE, response entropy; SE: state entropy; SEVO, sevoflurane; NA, not applicable.

Table 4. Study outcomes of the four groups of sevoflurane or desflurane anesthesia with or without M-Entropy guidance.

|                  | SEVO without M-Entropy | SEVO with M-Entropy | DES without M-Entropy | DES with M-Entropy |
|------------------|------------------------|---------------------|-----------------------|---------------------|
|                  | n = 40                 | n = 40              | n = 40                | n = 40              |
| Time to spontaneous eye opening, s | 409 (185, 982) | 463 (149, 982) | 371 (125, 778) | 218 (125, 778) | 0.0012 |
| Time to obeying commands, s | 532 (235, 1158) | 488 (210, 884) | 400 (180, 825) | 310 (130, 588) | 0.0001 |
| Time to tracheal extubation, s | 575 (235, 1060) | 503 (232, 1047) | 449 (205, 1144) | 313 (160, 617) | <0.0001 |
| Time to leaving operating room, s | 791 (443, 1372) | 851 (548, 1400) | 765 (450, 1255) | 569 (410, 865) | 0.0003 |
| Emergence agitation | 10 (3) | 3 | 7 | 5 | 0.0570 |
| Drowsiness after tracheal extubation | 0 | 0 | 0 | 0 | 0.1591 |
| Intraoperative awareness or recall | 0 | 0 | 0 | 0 | NA |
| Time percentage of RE > 60 | 23.0 | 26.4 | 10.5 | 7.2 | 12.5 | 0.0049 |
| Time percentage of SE ranged 40–60-60 | 53.3 | 71.1 | 48.7 | 7.5 | 82.9 | <0.0001 |
| Time percentage of RE < 40 | 10.0 | 1.3 | 33.2 | 0 | 0.99 | <0.0001 |
| Average RE value | 52 | 58 | 46 | 41 | 0.0003 |
| Time percentage of SE > 60 | 20.6 | 21.1 | 9.0 | 5.3 | 12.5 | 0.0111 |
| Time percentage of SE ranged 40–60-60 | 49.1 | 77.8 | 51.3 | 25.0 | 78.5 | 0.0003 |
| Time percentage of SE < 40 | 10.7 | 1.3 | 34.9 | 11.1 | 4.0 | <0.0001 |
Table 4. Cont.

|                               | SEVO without M-Entropy _n = 20_ | SEVO with M-Entropy _n = 20_ | DES without M-Entropy _n = 20_ | DES with M-Entropy _n = 20_ | _p_ |
|-------------------------------|---------------------------------|-------------------------------|---------------------------------|-------------------------------|-----|
| Average SE value             | 50 46, 62 (41, 68)              | 56 54, 59 (49, 66)            | 45 38, 53 (35, 60)              | 50 48, 53 (45, 60)            | 0.0001 |
| Average level of end-tidal SEVO, % | 1.66 1.57, 1.76 (1.21, 2.16) | 1.54 1.46, 1.83 (1.33, 2.29) | NA NA                           | NA NA                         | 0.4091 |
| Average level of end-tidal SEVO, aaMAC | 0.78 0.73, 0.83 (0.57, 0.99) | 0.73 0.69, 0.84 (0.63, 1.12) | NA NA                           | NA NA                         | 0.4165 |
| Average level of end-tidal DES, % | NA NA                           | NA NA                         | NA 4.85 (3.65, 6.85)            | 4.41 4.03, 5.09 (2.83, 5.95)  | 0.0531 |
| Average level of end-tidal DES, aaMAC | NA NA                           | NA NA                         | NA 0.73 (0.51, 0.95)            | 0.64 0.59, 0.75 (0.42, 0.85)  | 0.0358 |

Values are counts with percent or median with interquartile range (minimum and maximum). Abbreviation: aaMAC, age-adjusted minimum alveolar concentration; DES, desflurane; NA, not applicable; RE, response entropy; SE: state entropy; SEVO, sevoflurane.
Table 5. Intergroup comparisons for study outcomes.

|                          | SEVO/EG vs. SEVO/NEG | DES/NEG vs. SEVO/NEG | DES/EG vs. SEVO/NEG | DES/NEG vs. SEVO/EG | DES/EG vs. SEVO/EG | DES/EG vs. DES/NEG |
|--------------------------|----------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
|                          | MD or RD (99.2% CI)  | p                    | MD or RD (99.2% CI) | p                    | MD or RD (99.2% CI) | p                    |
| Time to spontaneous eye opening, s | 4 (–179, 186)        | 0.9532               | –55 (–237, 126)    | 0.3966               | –198 (–357, –39)    | 0.0014               | –59 (–222, 104)     | 0.3145               | –202 (–338, –66)     | 0.0002               | –142 (–276, –8)      | 0.0052               |
| Time to obeying commands, s | –34 (–214, 146)      | 0.5969               | –109 (–299, 81)    | 0.1175               | –245 (–412, –79)    | 0.0002               | –74 (–234, 85)      | 0.1992               | –211 (–337, –85)     | <0.0001              | –137 (–279, 6)       | 0.0106               |
| Time to tracheal extubation, s | 14 (–168, 196)       | 0.8302               | –65 (–272, 141)    | 0.3810               | –265 (–422, –107)   | <0.0001              | –79 (–279, 120)     | 0.2726               | –279 (–425, –132)    | <0.0001              | –199 (–379, –19)     | 0.0037               |
| Time to leaving operating room, s | 47 (–144, 237)       | 0.4946               | –30 (–223, 163)    | 0.6681               | –220 (–383, –57)    | 0.0005               | –77 (–271, 118)     | 0.2762               | –267 (–432, –102)    | <0.0001              | –190 (–358, –23)     | 0.0029               |
| Emergence agitation, % | –35.0 (–71.4, 1.4)  | 0.0181               | –15.0 (–56.0, 26.0) | 0.3373               | –35.0 (–71.4, 1.4)  | 0.0181               | 20.0 (–15.3, 55.3)  | 0.1441               | 0 (–30.0, 30.0)      | <0.0001              | –20.0 (–55.3, 15.3)  | 0.1441               |
| Drowsiness after tracheal extubation, % | 15.0 (–6.2, 36.2)  | 0.2308               | 10.0 (–7.8, 27.8)  | 0.4872               | NA                  | NA                  | –5.0 (–32.7, 22.7)  | >0.9999              | –15.0 (–36.2, 6.2)   | 0.2308               | –10.0 (–27.8, 7.8)   | 0.4872               |
| Intraoperative awareness or recall | 0 (0, 0)            | NA                   | 0 (0, 0)           | NA                   | 0 (0, 0)            | NA                   | 0 (0, 0)           | NA                   | 0 (0, 0)            | NA                   |
| Time percentage of RE > 60 | –2.7 (–21.9, 16.5)   | 0.6958               | –17.0 (–35.0, 0.9) | 0.0113               | –16.4 (–34.1, 1.3)  | 0.0130               | –14.3 (–27.4, –1.3) | 0.0039               | –13.7 (–26.5, 1.0)   | 0.0047               | 0.6 (–9.2, 10.4)     | 0.8630               |
| Time percentage of RE ranged 40–60 | 14.5 (–2.4, 31.4)  | 0.0210               | –4.9 (–24.2, 14.4) | 0.4832               | 27.0 (12.4, 41.6)   | <0.0001              | 19.4 (–37.7, –1.1)  | 0.0052               | 12.5 (–0.6, 25.6)    | 0.0115               | 31.9 (15.5, 48.3)    | <0.0001              |
| Time percentage of RE < 40 | –11.8 (–23.6, 0.1)   | 0.0083               | 21.9 (0.6, 43.3)   | 0.0066               | –10.6 (–22.7, 1.6)  | 0.0186               | 33.7 (14.5, 52.8)   | <0.0001              | 1.2 (–3.6, 6.0)      | 0.4890               | –32.5 (–51.8, –13.2) | <0.0001              |
| Average RE value | 4 (–3, 10)          | 0.1121               | –8 (–15, –0.2)     | 0.0067               | –2 (–8, 4)          | 0.3564               | –11 (–17, –5)      | <0.0001              | –6 (–9, –2)         | <0.0001              | –6 (–0.04, 11)       | 0.0084               |
| Time percentage of SE > 60 | –3.9 (–21.8, 14.1)   | 0.5499               | –15.6 (–32.6, 1.3) | 0.0137               | –14.6 (–31.1, 1.9)  | 0.0173               | –11.8 (–24.2, 0.7)  | 0.0119               | –10.7 (–22.5, 1.0)   | 0.0146               | 1.1 (–8.4, 10.5)     | 0.7558               |
| Time percentage of SE ranged 40–60 | 17.7 (1.4, 34.0)   | 0.0042               | –6.1 (–25.3, 13.1) | 0.3791               | 24.0 (9.5, 38.5)    | <0.0001              | –23.8 (–41.6, –6.0) | 0.0006               | 6.3 (–6.0, 18.6)     | 0.1583               | 30.1 (13.8, 46.5)    | <0.0001              |
| Time percentage of SE < 40 | –13.8 (–27.3, –0.4) | 0.0046               | 21.8 (0.5, 44.0)   | 0.0094               | –9.5 (–23.6, 4.7)   | 0.0656               | 41.2 (19.5, 63.0)   | <0.0001              | 4.4 (–2.2, 10.9)     | 0.0669               | –31.2 (–51.2, –11.2) | 0.0002               |
| Average SE value | 3 (–3, 10)          | 0.1253               | –7 (–15, –0.03)    | 0.0078               | –2 (–8, 4)          | 0.3404               | –11 (–16, –5)      | <0.0001              | –5 (–9, –2)         | 0.0001               | 5 (–0.3, 11)         | 0.0112               |
| Average level of end-tidal SEVO, % | 0.001 (–0.23, 0.23) | 0.9904               | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                   |
| Average level of end-tidal SEVO, aaMAC | –0.001 (–0.11, 0.11) | 0.9895               | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                   |
| Average level of end-tidal DES, % | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                   |
| Average level of end-tidal DES, aaMAC | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                  | NA                   | NA                   |

Abbreviation: aaMAC, age-adjusted minimum alveolar concentration; CI, confidence interval; DES, desflurane; EG, M-Entropy guidance; MD, mean difference; NA, not applicable; NEG, no M-Entropy guidance; RD, risk difference; RE, response entropy; SE: state entropy; SEVO, sevoflurane.
4. Discussion

In this randomized clinical trial, desflurane significantly accelerated emergence from anesthesia compared to sevoflurane in obese patients undergoing bariatric surgery. In addition, M-Entropy guidance for anesthetic depth further shortened the awakening time in patients receiving desflurane but not sevoflurane. Our results also suggested that M-Entropy guidance was effective in reducing the development of emergence agitation. These benefits were related to a shallower anesthetic depth, as demonstrated by the higher response and state entropy values in M-Entropy guidance groups. Our findings indicated that desflurane with M-Entropy guidance may serve as a practicable strategy for early and uneventful emergence from anesthesia in obese surgical patients.

Obese patients are prone to delayed emergence from general anesthesia and to the lasting respiratory depression effects of anesthetic agents [5,6]. However, there is still a lack of consensus regarding the optimal protocol to accelerate recovery from anesthesia in the obese population [7]. Clinical trials have reported that BIS-guided desflurane anesthesia not only achieve faster eye opening, airway reflex recovery, tracheal extubation, and orientation, but also increase modified Aldrete scores and oxygen saturations in postanesthesia care units compared to sevoflurane, isoflurane, and propofol [8–13]. However, other investigators refuted the advantages of desflurane over sevoflurane in immediate recovery [14–16]. These discrepancies might result from the heterogeneity in patients’ body mass indexes, administered adjuvant hypnotic drugs, anesthetic depth targets, and types of surgery [8–16].

Elbakry and colleagues recently showed that total intravenous anesthesia using propofol and dexmedetomidine was effective in reducing postoperative pain intensity, analgesic consumptions, and length of postanesthesia care unit stay among morbidly obese patients compared to desflurane anesthesia [24]. The time to achieve an Aldrete score of 10 was similar between the two methods, but emergence times and agitation were not assessed [24]. Given that the current pharmacokinetic models (e.g., Marsh and Schnider) may not be accurate in obese patients [25], more studies are needed to evaluate the optimal infusion regimens and clinical benefits of total intravenous anesthesia among obese patients in the context of enhanced recovery after surgery.

Few studies have investigated the benefits of EEG guidance of anesthetic depth in the immediate recovery from anesthesia in obese patients. In a randomized controlled trial, Ibraheim and colleagues reported that obese patients receiving BIS-guided sevoflurane anesthesia had significantly faster awakening and shorter extubation times, and lower sevoflurane consumption and medical costs compared to those without BIS monitoring [19]. However, this study was limited by a small patient sample and no evaluation of other anesthetics [19]. It is noteworthy that few studies have simultaneously investigated the impact of different anesthetic agents and EEG guidance on patients’ wake-up times. The present study showed that patients receiving desflurane combined with M-Entropy guidance had more rapid recovery compared to those with sevoflurane or without M-Entropy guidance. These results provide clinical insights to prevent delayed emergence from anesthesia following surgery for obese patients.

We propose the following possible mechanisms for the inconsistent effects of M-Entropy guidance on emergence time between sevoflurane and desflurane. First, awareness of faster wash-out and wake-up from desflurane compared to sevoflurane might contribute to the use of high concentrations of desflurane in the absence of anesthetic depth neuromonitoring, [8–13]. This was reflected by the higher end-tidal concentration of desflurane but not sevoflurane in patients without M-Entropy guidance. Second, De Baerdemaeker and colleagues showed that desflurane was associated with better hemodynamic controllability and lower risk of hypotension in obese patients compared to sevoflurane [9]. The anesthetists in the desflurane groups were perhaps less concerned about hypotension, which might have given rise to deeper anesthesia associated with desflurane when anesthesia was not guided by M-Entropy. Third, M-Entropy guidance increased the intraoperative time percentages of response entropy and state entropy ranging from 40 to 60 by 31.9%.
and 30.1% in desflurane, but only by 14.5% and 17.7% in sevoflurane. The difference in hypnotic controllability between sevoflurane and desflurane might explain our results.

Interestingly, our study demonstrated a potential benefit of M-Entropy guidance in reducing emergence agitation in obese adults following bariatric surgery. Studies have shown that obesity and inhalational anesthesia (especially anesthetics with low blood-gas solubility, such as sevoflurane and desflurane) are risk factors for agitation and delirium during emergence from anesthesia in adults [26,27]. However, to date, few studies have investigated the potential effect of EGG monitoring and emergence agitation in adults [28]. In children, studies have shown that neither deep hypnosis (BIS value < 45) nor prolonged emergence affects the risk of emergence agitation [29,30]. Moreover, we did not observe a significant difference in the risk of emergence agitation between sevoflurane and desflurane, in contrast with other studies [31]. Our findings warrant future studies to evaluate the effects of shallow or deep anesthesia, anesthetic depth guidance, and different anesthetic agents on the development of emergence agitation in obese patients.

This study had some limitations. First, the number of participants in the trial was modest, which may have given rise to some underpowered statistics in our intergroup comparisons. Second, the administration of volatile anesthetics was primarily based on clinical judgement and was not standardized by protocols. Consequently, the anesthetists’ preferences for different anesthesia practices might affect the generalizability of the study results. Third, we did not evaluate the use of volatile anesthetics and the medical cost of general anesthesia, which precluded a cost-benefit analysis of the different interventions applied in this study. Fourth, the anesthetists who titrated the volatile anesthetics according to entropy values or clinical signs during surgery could not be blinded, which might have biased the study results. Fifth, we did not evaluate total intravenous anesthesia, which may be protective against emergence agitation compared to inhalational anesthesia [32,33]. Sixth, the differences in times to emergence were approximately 2 to 5 min among the groups in our study; this possibly represents a low clinical significance in daily practice. Finally, the use of desflurane has been phased out in many countries in view of its impact on global warming [34]. Nevertheless, our results suggested that M-Entropy guidance can reduce the time percentage of deep anesthesia and the risk of emergence agitation in sevoflurane anesthesia. This finding has clinical implications in the anesthesia care of patients with obesity.

5. Conclusions

The use of desflurane to maintain general anesthesia significantly shortened the time to emergence from anesthesia in obese patients compared to sevoflurane. Additionally, the utilization of M-Entropy neuromonitoring to guide intraoperative depth of anesthesia further reduced the recovery time in patients receiving desflurane rather than sevoflurane. M-Entropy guidance might be effective in preventing the occurrence of emergence agitation. These findings provide evidence to facilitate the postoperative recovery from anesthesia and to decrease complications associated with delayed emergence and emergence agitation in obese patients undergoing surgery.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11010162/s1, Table S1: Intraoperative hemodynamic parameters.

Author Contributions: Conceptualization, H.-L.W. and Y.-H.T.; methodology, Y.-H.T.; software, Y.-H.T.; validation, S.-Y.H., H.-C.C. and P.-H.L.; formal analysis, Y.-H.T.; investigation, Y.-M.W., S.-Y.H., Y.-L.Y. and Y.-H.T.; resources, Y.-H.S. and Y.-H.T.; data curation, Y.-M.W., S.-Y.H., H.-C.C. and Y.-L.Y.; writing—original draft preparation, Y.-M.W.; writing—review and editing, Y.-H.S., J.-T.C., H.-C.C., Y.-G.C., H.-L.W. and Y.-H.T.; visualization, P.-H.L. and Y.-H.T.; supervision, Y.-H.S., J.-T.C., Y.-G.C., H.-C.C. and Y.-H.T.; project administration, Y.-M.W. and Y.-H.T.; funding acquisition, Y.-H.T. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the grants from Taipei Medical University (TMU110-AE1-B11), Taipei, Taiwan and Ministry of Science and Technology (MOST109-2314-B-038-024), Taipei, Taiwan.
Institutional Review Board Statement: This study was reviewed and approved by the Institutional Review Board of Taipei Medical University (TMU-JIRB-N202002076). It was registered in an international directory, www.clinicaltrials.gov (accessed on 27 September 2021) (identifier: NCT04395248). All methods of this study were performed in accordance with the Helsinki Declaration and relevant regulations.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the regulations of the Institutional Review Board.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization. Fact Sheets: Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 15 October 2021).
2. le Roux, C.W.; Chubb, B.; Nørtoft, E.; Borglykke, E. Obesity and healthcare resource utilization: Results from Clinical Practice Research Database (CPRD). Obes. Sci. Pract. 2018, 4, 409–416. [CrossRef]
3. Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298. [CrossRef]
4. Welbourn, R.; Hollyman, M.; Kinsman, R.; Dixon, J.; Liem, R.; Ottosson, J.; Ramos, A.; Våge, V.; Al-Sabah, S.; Brown, W. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes. Surg. 2019, 29, 782–795. [CrossRef] [PubMed]
5. Thomas, E.; Martin, F.; Pollard, B. Delayed recovery of consciousness after general anaesthesia. BJAnesth. 2000, 91, 714–719. [CrossRef] [PubMed]
6. Tait, A.R.; Voepel-Lewis, T.; Burke, C.; Kostrzewa, A.; Lewis, I. Incidence and risk factors for perioperative adverse respiratory events in children who are obese. Anesthesiology 2008, 108, 375–380. [CrossRef] [PubMed]
7. Thorell, A.; MacCormick, A.D.; Awas, S.; Reynolds, N.; Roulin, D.; Demartines, N.; Vignaud, M.; Alvarez, A.; Singh, P.M.; Lobo, D.N. Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery after Surgery (ERAS) Society Recommendations. World J. Surg. 2016, 40, 2065–2083. [CrossRef] [PubMed]
8. Juvin, P.; Vadam, C.; Malek, L.; Dupont, H.; Marmuse, J.P.; Desmonts, J.M. Postoperative recovery after desflurane, propofol, or isoflurane anesthesia among morbidly obese patients: A prospective, randomized study. Anesth. Analg. 2000, 91, 714–719. [CrossRef] [PubMed]
9. De Baeremaeker, L.E.C.; Struys, M.M.R.F.; Jacobs, S.T.E.F.A.N.; Den Blauwen, N.M.M.; Bossuyt, G.R.P.J.; Pattyn, P.; Mortier, E.P. Optimization of desflurane administration in morbidly obese patients: A comparison with sevoflurane using an “inhalation bolus” technique. Br. J. Anaesth. 2003, 91, 638–650. [CrossRef] [PubMed]
10. Strum, E.M.; Szenohradszki, J.; Kaufman, W.A.; Anthone, G.J.; Manz, I.L.; Lumb, P.D. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: A prospective, randomized study. Anesth. Analg. 2004, 99, 1848–1853. [CrossRef]
11. La Colla, L.; Albertin, A.; La Colla, G.; Mangano, A. Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. Br. J. Anaesth. 2007, 99, 353–358. [CrossRef] [PubMed]
12. McKay, R.E.; Malhotra, A.; Cakmakkaya, O.S.; Hall, K.T.; McKay, W.R.; Apfel, C.C. Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. Br. J. Anaesth. 2010, 104, 175–182. [CrossRef] [PubMed]
13. Kaur, A.; Jain, A.K.; Sehgal, R.; Sood, J. Hemodynamics and early recovery characteristics of desflurane versus sevoflurane in bariatric surgery. J. Anaesth. Clin. Pharmacol. 2013, 29, 36–40. [CrossRef]
14. Arain, S.R.; Barth, C.D.; Shankar, H.; Ebert, T.J. Choice of volatile anesthetic for the morbidly obese patient: Sevoflurane or desflurane. J. Clin. Anesth. 2005, 17, 413–419. [CrossRef] [PubMed]
15. De Baeremaeker, L.E.; Jacobs, S.; Den Blauwen, N.M.; Pattyn, P.; Herregods, L.L.; Mortier, E.P.; Struys, M.M. Postoperative results after desflurane or sevoflurane combined with remifentanil in morbidly obese patients. Obes. Surg. 2006, 16, 728–733. [CrossRef] [PubMed]
16. Vallejo, M.C.; Sah, N.; Phelps, A.L.; O’Donnell, J.; Romeo, R.C. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. J. Clin. Anesth. 2007, 19, 3–8. [CrossRef]
17. Lewis, S.R.; Pritchard, M.W.; Fawcett, L.J.; Punjasawadwong, Y. Bispectral index for improving intraoperative awareness and early postoperative recovery in adults. Cochrane Database Syst. Rev. 2019, 9, CD003843. [PubMed]
18. Pandazi, A.; Bourlioti, A.; Kostopanagiotou, G. Bispectral Index (BIS) monitoring in morbidly obese patients undergoing gastric bypass surgery: Experience in 23 patients. Obes. Surg. 2005, 15, 58–62. [CrossRef]
19. Ibraheim, O.; Alshaer, A.; Mazen, K.; El-Dawlatly, A.; Turkistani, A.; Alkathery, K.; Al-Zahrani, T.; Al-Dohayan, A.; Bukhari, A. Effect of bispectral index (BIS) monitoring on postoperative recovery and sevoflurane consumption among morbidly obese patients undergoing laparoscopic gastric banding. *Middle East J. Anesthesiol.* 2008, 19, 819–830.

20. Van Lancker, P.; Dillemans, B.; Bogaert, T.; Mulier, J.P.; De Kock, M.; Haspeslagh, M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. *Anaesthesia* 2011, 66, 721–725. [CrossRef]

21. Ely, E.W.; Truman, B.; Shintani, A.; Thomason, J.W.W.; Wheeler, A.P.; Gordon, S.; Francis, J.; Speroff, T.; Gautam, S.; Margolin, R.; et al. Monitoring sedation status over time in ICU patients: Reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003, 289, 2983–2991. [CrossRef]

22. Liu, F.L.; Cherng, Y.G.; Chen, S.Y.; Su, Y.H.; Huang, S.Y.; Lo, P.H.; Lee, Y.-Y.; Tam, K.-W. Postoperative recovery after anesthesia in morbidly obese patients: A systematic review and meta-analysis of randomized controlled trials. *Can. J. Anaesth.* 2015, 62, 907–917. [CrossRef]

23. Sample-Size Determination. In *Statistical Methods in Medical Research*; Armitage, P.; Berry, G.; Matthews, J.N.S. (Eds.) Blackwell Science: Malden, MA, USA, 2002; pp. 137–146.

24. Elbakry, A.E.; Sultan, W.E.; Ibrahim, E. A comparison between inhalational (desflurane) and total intravenous anaesthesia (propofol and dexmedetomidine) in improving postoperative recovery for morbidly obese patients undergoing laparoscopic sleeve gastrectomy: A double-blinded randomised controlled trial. *J. Clin. Anesth.* 2018, 45, 6–11. [PubMed]

25. Nimmo, A.F.; Absalom, A.R.; Bagshaw, O.; Biswas, A.; Cook, T.M.; Costello, A.; Grimes, S.; Mulvey, D.; Shinde, S.; Wiles, M.D. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. *Anesthesia* 2019, 74, 211–224. [CrossRef] [PubMed]

26. Fields, A.; Huang, J.; Schroeder, D.; Sprung, J.; Weingarten, T. Agitation in adults in the post-anaesthesia care unit after general anaesthesia. *Br. J. Anaesth.* 2018, 121, 1052–1058. [CrossRef]

27. Munk, L.; Andersen, G.; Møller, A.M. Post-anaesthetic emergence delirium in adults: Incidence, predictors and consequences. *Acta Anaesthesiol. Scand.* 2016, 60, 1059–1066. [CrossRef] [PubMed]

28. Lee, S.J.; Sung, T.Y. Emergence agitation: Current knowledge and unresolved questions. *Korean J. Anaesthesiol.* 2020, 73, 471–485. [CrossRef] [PubMed]

29. Faulk, D.J.; Twite, M.D.; Zuk, J.; Pan, Z.; Wallen, B.; Friesen, R.H. Hypnotic depth and the incidence of emergence agitation and negative postoperative behavioral changes. *Paediatr. Anaesth.* 2010, 20, 72–81. [CrossRef]

30. Oh, A.Y.; Seo, K.S.; Kim, S.D.; Kim, C.S.; Kim, H.S. Delayed emergence process does not result in a lower incidence of emergence agitation after sevoflurane anesthesia in children. *Acta Anaesthesiol. Scand.* 2005, 49, 297–299. [CrossRef]

31. Choi, G.J.; Baek, C.W.; Kang, H.; Park, Y.H.; Yang, S.Y.; Shin, H.Y.; Jung, Y.H.; Woo, Y.C.; Lee, U.L. Emergence agitation after orthognathic surgery: A randomised controlled comparison between sevoflurane and desflurane. *Acta Anaesthesiol. Scand.* 2015, 59, 224–231. [CrossRef]

32. Kim, M.S.; Moon, B.E.; Kim, H.; Lee, J.R. Comparison of propofol and fentanyl administered at the end of anesthesia for prevention of emergence agitation after sevoflurane anesthesia in children. *Br. J. Anaesth.* 2013, 110, 274–280. [CrossRef]

33. İslık, B.; Arslan, M.; Tunga, A.D.; Kurtipek, O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. *Painiatr. Anaesth.* 2006, 16, 748–753. [CrossRef] [PubMed]

34. Varughese, S.; Ahmed, R. Environmental and occupational considerations of anesthesia: A narrative review and update. *Anesth. Analg.* 2021, 133, 826–835. [CrossRef] [PubMed]